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Docosahexaenoic Acid Alleviates
Atopic Dermatitis in Mice by
Generating T Regulatory Cells and M2
Macrophages
Karyn A. Haitz1 and Niroshana Anandasabapathy1
Han et al. (this issue) describe a novel mechanism by which docosahexaenoic
acid (DHA) may suppress atopic dermatitis symptoms in mice. They ﬁnd that
DHA induces FoxP3 T regulatory cells in vivo, M2 macrophages drive
transforming growth factor-β and IL-10 conversion of CD4 T cells to CD4 FoxP3
T regulatory cells in vitro, and DHA-treated M2 macrophages suppress atopic
dermatitis in mice.
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In 1929, George and Mildred Burr
reported that a deﬁciency of essential
fatty acids in the diet of rats led to
increased transepidermal water loss and
skin abnormalities, including scaly skin,
inﬂamed tails, dandruff, loss of fur, and
sores (Burr and Burr, 1929,1930; Smith
and Mukhopadhyay, 2012). The animals
could be cured by administration of com-
plex unsaturated oils but not saturated
fatty acids. In humans, essential fatty
acid deﬁciency leads to dermatitis and
increased transepidermal water loss,
which can be reversed by the oral or
topical administration of essential fatty
acids (Hansen et al., 1958; Prottey et al.,
1975). These early studies paved the way
to the use of fatty acid supplementation to
treat a variety of inﬂammatory disorders,
including the use of ﬁsh oil containing
docosahexaenoic acid (DHA), an omega-3
(n= 3) long chained polyunsaturated
fatty acid (PUFA). As atopic dermatitis
rates have tripled in the past 30 years,
affecting 10–20% of children and 1–3%
of adults, altered lipid composition of
the diet has been investigated (Calder,
2006, 2013). Additional associations
with increased body hygiene (hygiene
hypothesis) and genetics (Boguniewicz
and Leung, 2011) have been identiﬁed.
Several clinical trials have addressed
the beneﬁcial effects of DHA supple-
mentation on atopic dermatitis (Koch
et al., 2008), allergy (Birch et al., 2010),
and atopic outcomes for infants whose
mothers took DHA supplementa-
tion during pregnancy and lactation
(Furuhjelm et al., 2011). The outcome
of fatty acid supplementation during
pregnancy and during early childhood
for atopy and allergy is an area of
active investigation. Noakes et al. (2012)
reported decreased cord blood cyto-
kine responses to immune agonists after
salmon supplementation, including
1160mg/day DHA, during the last
20 weeks of pregnancy. However, they
observed no differences in IgE at birth,
total IgE at 6 months of age, incidence
and severity of atopic dermatitis at
6 months of age, and skin-prick-test
positivity at 6 months of age. A rando-
mized double-blinded trial demonstrated
that infants given DHA- and arachidonic
acid (ARA)-supplemented formula during
the ﬁrst year of life had lower allergic
outcomes at 3 years of age (Birch et al.,
2010). The DHA/ARA group (n=38/89
infants) had signiﬁcantly lower odds for
developing upper respiratory infections,
wheezing/asthma, wheezing/asthma/ato-
pic dermatitis, or any other allergy,
whereas controls had signiﬁcantly shor-
ter times to ﬁrst diagnosis of upper
respiratory infections, wheezing/asthma,
or any other allergy. In another study, 145
pregnant women at risk for having an
allergic infant were randomized to daily
supplementation with eicosapentaenoic
acid (EPA) and DHA or placebo from
the 25th gestational week, continuing
through 3.5 months of breastfeeding
(Furuhjelm et al., 2011). Although no
differences in the prevalence of allergic
symptoms were found between groups,
the decreased cumulative incidence of
IgE-associated disease observed during
the ﬁrst year persisted until 2 years of
age. High proportions of DHA and EPA in
maternal and infant plasma phospholipids
correlated with reduced severity of the
allergic phenotype.
In a randomized controlled trial of
53 adult patients with atopic dermatitis
who received 5400mg per day of DHA
over 8 weeks, the DHA-treated indivi-
duals had fewer atopic symptoms, on
the basis of the SCORAD, a severity
scoring scale (Koch et al., 2008). Ex vivo
peripheral blood mononuclear cells
from patients with atopic dermatitis
who were given DHA had signiﬁcantly
reduced IgE secretion levels when
stimulated with anti-CD40 and IL-4,
compared with control subjects (Koch
et al., 2008). This IgE difference may
not have been seen in earlier studies
because of lower amounts of DHA
supplementation, indirect DHA supple-
mentation through the mothers, or
differing DHA effects in infants vs.
adults.
Cumulatively, these studies are pro-
mising, and they suggest DHA supple-
mentation as a means of improving the
symptoms of atopic dermatitis. Clinical
trials continue to investigate the out-
comes of allergic disease and atopy, as
related to omega-3 fatty acid, and
speciﬁcally DHA supplementation. In
parallel, the underlying immune-
mediated mechanisms by which atopic
dermatitis is mediated, particularly in
barrier tissues such as the lung and the
skin, are in progress. Normally, when
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the stratum corneum barrier is dehy-
drated, breakdown products of ﬁlaggrin
act as osmolytes to hydrate its corneo-
cytes (Boguniewicz and Leung, 2011).
The most signiﬁcant genetic predispo-
sition to atopic dermatitis is loss of
function mutations in the FLG gene
coding ﬁlaggrin, which alters the skin
barrier of patients with atopic disease by
decreasing stratum corneum hydration
(Cork et al., 2009). Disruption of the
epidermal barrier can also lead to atopy
through environmental means, such as
the excessive use of soap and deter-
gents, which raises the pH, increasing
protease activity and decreasing
synthesis of the lipid lamellae which,
in turn, encases the corneocytes to
prevent water loss (Cork et al., 2009).
In addition to the role of barrier
defect, innate and adaptive immunity
has been studied in atopic disease. Ma
et al. (2014) found that there were
decreased levels of T regulatory cells,
FoxP3, and TGF-β (transforming growth
factor-β) mRNA and increased levels of
Th17 (T helper type 17), IL-17, and
IL-23 in the peripheral blood of patients
with atopic dermatitis compared with
healthy control patients, with the sever-
ity of atopic dermatitis correlating posi-
tively with Th17 levels and negatively
with T regulatory cell levels. Macro-
phages have also been implicated;
macrophage numbers are increased in
atopic dermatitis compared with normal
skin, with a mixture of M1 and M2
macrophages, but the roles of these
macrophage subtypes in the different
inﬂammatory phases of atopic dermati-
tis have not yet been determined
(Kasraie and Werfel, 2013). Dendritic
cell numbers do not change in atopic
dermatitis, but there is increased
overlap between the macrophage and
dendritic cell phenotypes, suggesting
the possibility of heterogeneous
dendritic cell/macrophage populations
in the skin of patients with atopic
dermatitis (Kiekens et al., 2001).
Now Han et al. (this issue, 2015)
report a potential cellular immune
mechanism for DHA in suppressing
allergy and atopic dermatitis in pre-
clinical mouse models (Figure 1). They
observed that DHA supplementation
suppresses the development of atopic
dermatitis in mice, with consonant
reductions in Serum IgE (a major acti-
vator of mast cells), histamine produc-
tion, ear thickness, and a signiﬁcant
reduction in lymph node size. Several
possible potential mechanisms are pre-
sented. DHA was observed to induce a
2-fold greater T regulatory cell expres-
sion of CTLA4, a T-cell inhibitory
receptor associated with tolerance.
DHA induced TGF-β, which could then
induce FoxP3 T regulatory cells, and
DHA enhanced M2 macrophage func-
tion, which in turn could enhance TGF-
β production. Indeed, transfusion of
DHA-M2 macrophages protected
against atopic dermatitis and induced
T regulatory cells in sites of inﬂamma-
tion. However, the transfusion of DHA-
M2 macrophages should be compared
with transfusion of M2 macrophages
alone to detect whether there is an
additional beneﬁt.
This study ﬁnds optimal beneﬁts
of DHA supplementation in mice at
100mg kg− 1 per day, with 50mg kg−1
per day being the minimal effective
dose (Han et al., 2015). This corres-
ponds to 3,500–7,000mg in a standard
70 kg human, which correlates with the
range administered in clinical trials in
which beneﬁt was seen (Koch et al.,
2008). Of note, the therapeutic dose
needed in both of these studies exceeds
the 90–450mg DHA in standard open-
label omega-3 fatty acid supplements
(Laidlaw et al., 2014). However,
patients in the former study had excel-
lent DHA tolerability with only three
participants reporting slight GI dis-
comfort and no other reported side
effects, suggesting 5400mg per day as
an acceptable level of DHA (Koch et al.,
2008). Because this dosing corresponds
to the DHA levels given to the mice,
changes in cytokine proﬁles and T
regulatory cell upregulation with DHA
Clinical Implications
● High amounts of supplemental docosahexaenoic acid (DHA; 100mg kg− 1
per day) may improve the symptoms of atopic dermatitis in mouse
models.
● DHA stimulates FoxP3 T regulatory cell generation, which suppresses
inﬂammation.
● DHA may alleviate symptoms of patients with atopic dermatitis via M2
macrophage induction of FoxP3 T regulatory cells.
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Figure 1. DHA suppression of atopic dermatitis symptoms potentially occurs through T regulatory cells
and M2 macrophages. Han et al. (2015) found that DHA decreases atopic dermatitis symptoms and
increases FoxP3 T regulatory cells in vivo. In this model, DHA directly increases TGF-β mediated
conversion of CD4 T cells to CD4 FoxP3 T regulatory cells and induces M2 macrophages to drive TGF-β
and IL-10 conversion of CD4 T cells to CD4 FoxP3 T regulatory cells in vitro. DHA-M2 macrophage
injection leads to better control of atopic dermatitis in vivo compared with no treatment. These ﬁndings
suggest that there may be a role for M2 macrophages in preferentially mediating the conversion of CD4
T cells to CD4 FoxP3 T regulatory cells in atopic dermatitis. DHA, docosahexanoic acid; TGF-β,
transforming growth factor-β; Treg cell, T regulatory cell.
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supplementation in this mouse model
of atopic dermatitis may correlate
with the changes that occur in humans
with atopic dermatitis who are given
equivalent DHA doses (Han et al.,
2015).
There is little data in the literature
related to changes in cytokine signaling
in humans after taking supplemental
DHA. One review addressed the effects
of omega-3 fatty acid (DHA and EPA) in
various inﬂammatory conditions (Sijben
and Calder, 2007), and suggested that
omega-3 fatty acids may decrease
inﬂammatory markers in certain inﬂam-
matory conditions such as inﬂammatory
bowel disease. Other notable ﬁndings
were that local rather than systemic
inﬂammatory cytokines correlated with
clinical outcomes in inﬂammatory lung
diseases. In certain conditions like
rheumatoid arthritis clinical improve-
ment was more signiﬁcant compared
with inﬂammatory cytokine proﬁle
changes after omega-3 fatty acid sup-
plementation (Sijben and Calder, 2007).
In neurobiology, DHA has been
found to be one of the few substances
that reduces the risk of Alzheimer’s
disease, with patients consuming ﬁsh
once or more per week having 60% less
risk of Alzheimer’s disease compared
with those who never or rarely eat ﬁsh
(Morris et al., 2003). Furthermore, in
this study, total intake of n-3 PUFAs and
DHA, but not EPA, correlated with a
reduced risk of Alzheimer’s disease.
DHA was found to beneﬁt patients
with Alzheimer’s disease by enhancing
Aβ42 phagocytosis by microglia with
predominantly M2 markers and by
shifting away from pro-inﬂammatory
M1 macrophage activation and pro-
inﬂammatory cytokines (Hjorth et al.,
2013).
A randomized controlled trial in
which DHA and EPA supplementation
was given to Alzheimer’s disease
patients showed that IL-6, IL-1β, and
granulocyte colony–stimulating factor
secretion are decreased when periph-
eral blood mononuclear cells are
stimulated with lipopolysaccharide
(LPS) after 6 months of 1,700mg
per day DHA and 600mg per day EPA
(Vedin et al., 2008). Similarly Han et al.
have shown that secretion of IL-6 is
decreased in LPS-stimulated macro-
phages and that IL-1β, IL-6, and TNF-α
expression are decreased in M1 macro-
phages that are co-cultured with M2
macrophages for 24 hours (Han et al.,
2015). The decrease in IgE in DHA-fed
mice parallels the ex vivo IgE secretion
of stimulated peripheral blood mono-
nuclear cells from DHA-supplemented
patients (Koch et al., 2008).
The use of DHA for autoimmunity
and inﬂammation is increasingly com-
mon, but little has been done to
rigorously study the effects of DHA on
immunity outside of a neurobiology
context or outside of the lipid literature.
Future clinical trials will likely look at
DHA effects in a larger population of
patients with atopic dermatitis, measur-
ing both clinical outcomes and changes
in inﬂammatory cell and cytokine pro-
ﬁles. Future studies may address the use
of high DHA doses to treat atopic
individuals, and they may also address
the additional mechanistic clues con-
cerning how DHA can modulate the
immune system to improve symptoms
in atopic dermatitis and other autoim-
mune and inﬂammatory conditions.
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